Company Description
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
The company develops programs related to the treatment of disc/spine disease and metabolic disorders.
Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body.
The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011.
BioRestorative Therapies, Inc. is headquartered in Melville, New York.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Lance Alstodt |
Contact Details
Address: 40 Marcus Drive, Suite 1 Melville, New York 11747 United States | |
| Phone | 631 760 8100 |
| Website | biorestorative.com |
Stock Details
| Ticker Symbol | BRTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1505497 |
| CUSIP Number | 090655606 |
| ISIN Number | US0906556065 |
| Employer ID | 30-1341024 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Lance Alstodt | Chairman of the Board, President and Chief Executive Officer |
| Robert Eugene Kristal | Chief Financial Officer |
| Francisco J. Silva | Vice President of Research and Development, Secretary and Director |
| Crystal Romano | Head of Global Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2026 | 8-K | Current Report |
| Apr 30, 2026 | 424B3 | Prospectus |
| Apr 28, 2026 | EFFECT | Notice of Effectiveness |
| Apr 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 23, 2026 | 8-K | Current Report |
| Apr 20, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 13, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 26, 2026 | 10-K | Annual Report |
| Feb 23, 2026 | SCHEDULE 13G/A | Filing |